SLC5A2 and atherosclerosis: The Dapagliflozin Effect on Cardiovascular Events—Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial was a large cardiovascular outcome trial that enrolled over 17,000 participants with T2D and existing atherosclerotic cardiovascular disease (ASCVD) or its risk factors.13 When compared with cardiovascular outcome trials for other SGLT2 inhibitors, DECLARE-TIMI 58 included a smaller fraction of participants with established ASCVD at baseline, representing a lower-risk population overall (Table 1).